Docket Room.
SB 256·NH·senate

establishing safety and care requirements for clinician-administered drugs.

FailedFiled Jan 23, 2025
Latest Action

Interim Study Report: Not Recommended for Future Legislation 10/15/2026 (Vote 11-0; )

Oct 19, 2026

Summary

The bill defines clinician‑administered drugs and bars health insurers or pharmacy benefit managers from requiring ‘white‑bagging’ or ‘brown‑bagging’ unless written agreements and consent are obtained. It also stops them from limiting coverage, raising costs, or penalizing providers who use non‑network pharmacies. The aim is to keep drug administration safe and preserve patient and provider choice.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Share

Track this bill

Get an email when SB 256 moves: committee action, floor votes, amendments and hearings. Free, no card.

Track SB 256 free

Or ask your AI assistant about SB 256 directly:

Add to Claude, ChatGPT or Cursor
Docket Room · Nonpartisan legislative tracking
Docket Room IntelligencePro

Ask about your legislation

I can analyze your tracked bills, upcoming hearings, and recent changes.

AI-generated · Nonpartisan · Not legal advice